Imperial College London
Alternate

ProfessorPeterSever

Faculty of Medicine, National Heart & Lung Institute

Professor of Clinical Pharmacology & Therapeutics
 
 
 
//

Contact

 

+44 (0)20 7594 1099p.sever

 
 
//

Assistant

 

Mrs Yvonne Green +44 (0)20 7594 1100

 
//

Location

 

333ICTEM buildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Fagundes:2022:10.1016/j.jacc.2022.05.051,
author = {Fagundes, A and Morrow, DA and Oyama, K and Furtado, RHM and Zelniker, TA and Tang, M and Kuder, JF and Murphy, SA and Hamer, A and Keech, AC and Sever, P and Giugliano, RP and Sabatine, MS and Bergmark, BA},
doi = {10.1016/j.jacc.2022.05.051},
journal = {Journal of the American College of Cardiology},
pages = {887--897},
title = {Biomarker prediction of complex coronary revascularization procedures in the FOURIER trial},
url = {http://dx.doi.org/10.1016/j.jacc.2022.05.051},
volume = {80},
year = {2022}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BackgroundBiomarkers are known to predict major adverse cardiovascular events. However, the association of biomarkers with complex coronary revascularization procedures or high-risk coronary anatomy at the time of revascularization is not understood.ObjectivesWe examined the associations between baseline biomarkers and major coronary events (MCE) and complex revascularization procedures.MethodsFOURIER was a randomized trial of the proprotein convertase subtilisin–kexin type 9 inhibitor evolocumab vs placebo in 27,564 patients with stable atherosclerosis. We analyzed adjusted associations among the biomarkers, MCE (coronary death, myocardial infarction, or revascularization), and complex revascularization (coronary artery bypass graft or complex percutaneous coronary intervention) using a multimarker score with 1 point assigned for each elevated biomarker (high-sensitivity C-reactive protein ≥2 mg/L; N-terminal pro–B-type natriuretic peptide ≥450 pg/mL; high-sensitivity troponin I ≥6 ng/L; growth-differentiation factor-15 ≥1,800 pg/mL).ResultsWhen patients were grouped by the number of elevated biomarkers (0 biomarkers, n = 6,444; 1-2 biomarkers, n = 12,439; ≥3 biomarkers, n = 2,761), there was a significant graded association between biomarker score and the risk of MCE (intermediate score: HRadj: 1.57 [95% CI: 1.38-1.78]; high score: HRadj: 2.90 [95% CI: 2.47-3.40]), and for complex revascularization (intermediate: HRadj: 1.33 [95% CI: 1.06-1.67]; high score: HRadj: 2.07 [95% CI: 1.52-2.83]) and its components (Ptrend <0.05 for each). The number of elevated biomarkers also correlated with the presence of left main disease, multivessel disease, or chronic total occlusion at the time of revascularization (P < 0.05 for each).ConclusionsA biomarker-based strategy identifies stable patients at risk for coronary events, including coronary artery bypass graft surgery and complex percutaneous coronary intervention, and predicts high-risk cor
AU  - Fagundes,A
AU  - Morrow,DA
AU  - Oyama,K
AU  - Furtado,RHM
AU  - Zelniker,TA
AU  - Tang,M
AU  - Kuder,JF
AU  - Murphy,SA
AU  - Hamer,A
AU  - Keech,AC
AU  - Sever,P
AU  - Giugliano,RP
AU  - Sabatine,MS
AU  - Bergmark,BA
DO  - 10.1016/j.jacc.2022.05.051
EP  - 897
PY  - 2022///
SN  - 0735-1097
SP  - 887
TI  - Biomarker prediction of complex coronary revascularization procedures in the FOURIER trial
T2  - Journal of the American College of Cardiology
UR  - http://dx.doi.org/10.1016/j.jacc.2022.05.051
UR  - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000861033600005&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=a2bf6146997ec60c407a63945d4e92bb
UR  - https://www.sciencedirect.com/science/article/pii/S0735109722054225
UR  - http://hdl.handle.net/10044/1/104544
VL  - 80
ER  -
Download